In this episode of Raising Biotech, host Surani Fernando uncovers the mission of Sparrow Pharmaceuticals with David Katz, founder and Chief Scientific Officer. Joined by Dr. Peter Merkel, Chief of the Division of Rheumatology at the University of Pennsylvania, and Dr. Leon Henderson MacLennan, co-founder of InThought Research, they explore Sparrow’s ambitious quest to tackle the damaging effects of steroids after raising a $50 million Series A.
Sparrow Pharmaceuticals is taking on a widespread issue: the harmful side effects of glucocorticoids, which are commonly prescribed for autoimmune and inflammatory conditions like rheumatoid arthritis and asthma. Katz explains that their lead asset, an HSD1 inhibitor, aims to maintain the therapeutic benefits of steroids while reducing their harmful effects, such as bone damage and metabolic disruptions. By targeting cortisol imbalances linked to conditions like Cushing’s syndrome and autonomous cortisol secretion, Sparrow is developing what could be a game-changing solution in the steroid space.
The idea for Sparrow came from Katz’s years in big pharma, where he saw firsthand the gap in addressing steroid toxicity. While most people would be considering retirement, Katz took a different path—founding Sparrow with a mission to solve this long-ignored issue. “I had the ability to do something impactful,” he shared, highlighting his motivation to make a difference when he could have easily stepped away.
Sparrow is currently running three Phase II trials, targeting polymyalgia rheumatica, Cushing’s syndrome, and autonomous cortisol secretion. Dr. Merkel stressed the urgent need for safer steroid alternatives, pointing out that while steroids work, their side effects are a heavy burden for patients. Dr. MacLennan added that Sparrow’s focus on overlooked patient groups fills a critical gap in the market, bringing hope to those who have had limited options.
With $50 million raised in Series A funding, Sparrow is set to move forward but will need more financing to push through clinical trials. Katz revealed the company is keeping all options open—whether staying private, seeking partnerships, and acquisition or eventually going public. "Whatever gets the drug to people who need it is what I want," Katz stated, underscoring Sparrow’s patient-first approach.
Want to hear more about how Sparrow Pharmaceuticals is tackling one of medicine’s long-standing challenges and what their next steps could be? Tune into this episode of Raising Biotech for the full story on their strategy, clinical progress, and future plans.
[This episode was published on 4 June 2024]